Injectable medication that combines the effects of GLP-1 and GIP hormones for the treatment of type 2 diabetes

Injectable medication that combines the effects of GLP-1 and GIP hormones for the treatment of type 2 diabetes

Injectable medication that combines the effects of GLP-1 and GIP hormones for the treatment of type 2 diabetes

Injectable medication that combines the effects of GLP-1 and GIP hormones for the treatment of type 2 diabetes

Injectable medication that combines the effects of GLP-1 and GIP hormones for the treatment of type 2 diabetes

CONCENTRATION

CONCENTRATION

CONCENTRATION

CONCENTRATION

CONCENTRATION

Tirzepatide

Tirzepatide

Tirzepatide

Tirzepatide

Tirzepatide

60mg/3mL

60mg/3mL

60mg/3mL

60mg/3mL

PHARMACEUTICAL FORM

PHARMACEUTICAL FORM

PHARMACEUTICAL FORM

PHARMACEUTICAL FORM

PHARMACEUTICAL FORM

Injectable solution

Injectable solution

Injectable solution

Injectable solution

Injectable solution

1 vial 60 mg of Tirzepatide (Lyophilized Powder)

1 vial 3 ml of bacteriostatic water

1 vial 60 mg of Tirzepatide (Lyophilized Powder)

1 vial 3 ml of bacteriostatic water

Efficacy

Tirzepatide is a dual agonist of the GIP and GLP-1 receptors, designed to enhance glycemic control in patients with type 2 diabetes.

Its mechanism of action involves stimulation of glucose-dependent insulin secretion, suppression of glucagon release, delayed gastric emptying, and improved insulin sensitivity.

GIP receptor activation contributes to enhanced insulinotropic effects, while GLP-1 receptor activation supports weight reduction and metabolic improvements. Together, these pathways produce a synergistic effect on glucose metabolism with a favorable safety profile.

Tirzepatide is a dual agonist of the GIP and GLP-1 receptors, designed to enhance glycemic control in patients with type 2 diabetes.

Its mechanism of action involves stimulation of glucose-dependent insulin secretion, suppression of glucagon release, delayed gastric emptying, and improved insulin sensitivity.

GIP receptor activation contributes to enhanced insulinotropic effects, while GLP-1 receptor activation supports weight reduction and metabolic improvements. Together, these pathways produce a synergistic effect on glucose metabolism with a favorable safety profile.

Tirzepatide is a dual agonist of the GIP and GLP-1 receptors, designed to enhance glycemic control in patients with type 2 diabetes.

Its mechanism of action involves stimulation of glucose-dependent insulin secretion, suppression of glucagon release, delayed gastric emptying, and improved insulin sensitivity.

GIP receptor activation contributes to enhanced insulinotropic effects, while GLP-1 receptor activation supports weight reduction and metabolic improvements. Together, these pathways produce a synergistic effect on glucose metabolism with a favorable safety profile.

DadosFinalidadeDescrição
Dados de CadastroRealizar o cadastro; Realizar identificação dos Usuários junto à PlataformaDescrição detalhada dos dados de cadastro.
Dados de AtividadePersonalização da Plataforma de acordo com a experiência do usuárioDescrição detalhada dos dados de atividade.

About

Tirzepatide

About

Tirzepatide

Tirzepatide is a synthetic peptide and dual receptor agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Its dual mechanism enhances insulin secretion, suppresses glucagon, delays gastric emptying, and promotes weight reduction. Tirzepatide has demonstrated consistent efficacy and a favorable safety profile in clinical trials.

Tirzepatide is a synthetic peptide and dual receptor agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Its dual mechanism enhances insulin secretion, suppresses glucagon, delays gastric emptying, and promotes weight reduction. Tirzepatide has demonstrated consistent efficacy and a favorable safety profile in clinical trials.

Indications

Indications

Indicated as an adjunct to diet and physical activity to improve glycemic control in adults with type 2 diabetes mellitus.

Indicated as an adjunct to diet and physical activity to improve glycemic control in adults with type 2 diabetes mellitus.

Indicated as an adjunct to diet and physical activity to improve glycemic control in adults with type 2 diabetes mellitus.

Dosage

Dosage

The medication must be administered subcutaneously in the abdomen, thigh, or upper arm. Each vial contains 60 mg of Tirzepatide, reconstituted with 3 mL of bacteriostatic water for injection, yielding a concentration of 20 mg/mL.

The recommended starting dose is 2.5 mg (0.25 mL), once weekly. The dose may be increased in 2.5 mg increments every 4 weeks, based on clinical response and tolerability, up to a maximum of 15 mg (1.5 mL) per week.

Dosage should be measured using an appropriate syringe and must be determined by a licensed healthcare provider.

The medication must be administered subcutaneously in the abdomen, thigh, or upper arm. Each vial contains 60 mg of Tirzepatide, reconstituted with 3 mL of bacteriostatic water for injection, yielding a concentration of 20 mg/mL.

The recommended starting dose is 2.5 mg (0.25 mL), once weekly. The dose may be increased in 2.5 mg increments every 4 weeks, based on clinical response and tolerability, up to a maximum of 15 mg (1.5 mL) per week.

Dosage should be measured using an appropriate syringe and must be determined by a licensed healthcare provider.

Dados de CadastroRealizar o cadastro; Realizar identificação dos Usuários junto à PlataformaDescrição detalhada dos dados de cadastro.
Dados de AtividadePersonalização da Plataforma de acordo com a experiência do usuárioDescrição detalhada dos dados de atividade.

Drug Interactions

Drug Interactions

Tirzepatide may delay gastric emptying, potentially affecting the pharmacokinetics of concomitantly administered oral medications. While clinically relevant interactions have not been consistently demonstrated, caution is advised. Use should be guided by a qualified healthcare professional.

Tirzepatide may delay gastric emptying, potentially affecting the pharmacokinetics of concomitantly administered oral medications. While clinically relevant interactions have not been consistently demonstrated, caution is advised. Use should be guided by a qualified healthcare professional.

Tirzepatide may delay gastric emptying, potentially affecting the pharmacokinetics of concomitantly administered oral medications. While clinically relevant interactions have not been consistently demonstrated, caution is advised. Use should be guided by a qualified healthcare professional.

Adverse Reactions

Adverse Reactions

Gastrointestinal adverse events were the most commonly reported and were typically mild to moderate in severity. Nausea, vomiting, and diarrhea were more frequent during the initial dose titration phase and tended to diminish with continued treatment.

Gastrointestinal adverse events were the most commonly reported and were typically mild to moderate in severity. Nausea, vomiting, and diarrhea were more frequent during the initial dose titration phase and tended to diminish with continued treatment.

Gastrointestinal adverse events were the most commonly reported and were typically mild to moderate in severity. Nausea, vomiting, and diarrhea were more frequent during the initial dose titration phase and tended to diminish with continued treatment.

Storage

Storage

Store the lyophilized powder at room temperature, below 30 °C. Do not freeze. Protect from light and moisture.

Store the lyophilized powder at room temperature, below 30 °C. Do not freeze. Protect from light and moisture.

Store the lyophilized powder at room temperature, below 30 °C. Do not freeze. Protect from light and moisture.

After reconstitution with bacteriostatic water, store the solution in a refrigerator at 2 °C to 8 °C. Use within 21 days. Discard any unused reconstituted solution after this period.

After reconstitution with bacteriostatic water, store the solution in a refrigerator at 2 °C to 8 °C. Use within 21 days. Discard any unused reconstituted solution after this period.

After reconstitution with bacteriostatic water, store the solution in a refrigerator at 2 °C to 8 °C. Use within 21 days. Discard any unused reconstituted solution after this period.

Nauck MA, D’Alessio DA. Tirzepatide... effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol, 2022

Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. NEJM, 2021

Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. NEJM, 2022

Tian Q et al. Efficacy and safety of tirzepatide for weight loss... Frontiers in Endocrinology, 2025

Nauck et al. Tirzepatide, a dual GIP/GLP‑1 receptor co‑agonist … unprecedented effectiveness regarding glycaemic control and body weight reduction. Cardiovascular Diabetology, 2022

Nauck MA, D’Alessio DA. Tirzepatide... effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol, 2022

Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. NEJM, 2021

Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. NEJM, 2022

Tian Q et al. Efficacy and safety of tirzepatide for weight loss... Frontiers in Endocrinology, 2025

Nauck et al. Tirzepatide, a dual GIP/GLP‑1 receptor co‑agonist … unprecedented effectiveness regarding glycaemic control and body weight reduction. Cardiovascular Diabetology, 2022

Nauck MA, D’Alessio DA. Tirzepatide... effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol, 2022

Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. NEJM, 2021

Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. NEJM, 2022

Tian Q et al. Efficacy and safety of tirzepatide for weight loss... Frontiers in Endocrinology, 2025

Nauck et al. Tirzepatide, a dual GIP/GLP‑1 receptor co‑agonist … unprecedented effectiveness regarding glycaemic control and body weight reduction. Cardiovascular Diabetology, 2022

Safe Pro Labs™ is a biotechnology laboratory dedicated to metabolic innovation through peptides. Our compounds are formulated for licensed medical use. No sales or prescriptions are conducted through this site.

© 2025 Safe Pro Labs. All rights reserved.

Data Privacy

Cookie Privacy

Cookie Settings

Safe Pro Labs™ is a biotechnology laboratory dedicated to metabolic innovation through peptides. Our compounds are formulated for licensed medical use. No sales or prescriptions are conducted through this site.

© 2025 Safe Pro Labs. All rights reserved.

Data Privacy

Cookie Privacy

Cookie Settings

Safe Pro Labs™ is a biotechnology laboratory dedicated to metabolic innovation through peptides. Our compounds are formulated for licensed medical use. No sales or prescriptions are conducted through this site.

© 2025 Safe Pro Labs. All rights reserved.

Data Privacy

Cookie Privacy

Cookie Settings

Safe Pro Labs™ is a biotechnology laboratory dedicated to metabolic innovation through peptides. Our compounds are formulated for licensed medical use. No sales or prescriptions are conducted through this site.

© 2025 Safe Pro Labs. All rights reserved.

Data Privacy

Cookie Privacy

Cookie Settings

Safe Pro Labs™ is a biotechnology laboratory dedicated to metabolic innovation through peptides. Our compounds are formulated for licensed medical use. No sales or prescriptions are conducted through this site.

© 2025 Safe Pro Labs. All rights reserved.

Data Privacy

Cookie Privacy

Cookie Settings

Safe Pro Labs™ is a biotechnology laboratory dedicated to metabolic innovation through peptides. Our compounds are formulated for licensed medical use. No sales or prescriptions are conducted through this site.

© 2025 Safe Pro Labs. All rights reserved.

Data Privacy

Cookie Privacy

Cookie Settings